Effector Therapeutics Stock Performance
| EFTR Stock | USD 0.0002 0.0004 66.67% |
Effector Therapeutics holds a performance score of 10 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of 9.79, which means a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Effector Therapeutics will likely underperform. Use Effector Therapeutics mean deviation, jensen alpha, as well as the relationship between the Jensen Alpha and rate of daily change , to analyze future returns on Effector Therapeutics.
Risk-Adjusted Performance
Fair
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Effector Therapeutics are ranked lower than 10 (%) of all global equities and portfolios over the last 90 days. Even with relatively fragile basic indicators, Effector Therapeutics reported solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 8.7 M | |
| Total Cashflows From Investing Activities | 14.5 M | |
| Free Cash Flow | -29.6 M |
Effector Therapeutics Relative Risk vs. Return Landscape
If you would invest 0.02 in Effector Therapeutics on September 2, 2025 and sell it today you would earn a total of 0.00 from holding Effector Therapeutics or generate 0.0% return on investment over 90 days. Effector Therapeutics is currently generating 5.404% in daily expected returns and assumes 41.7062% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Effector, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Effector Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Effector Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Effector Therapeutics, and traders can use it to determine the average amount a Effector Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1296
| Best Portfolio | Best Equity | EFTR | ||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 41.71 actual daily | 96 96% of assets are less volatile |
Expected Return
| 4.96 actual daily | 96 96% of assets have lower returns |
Risk-Adjusted Return
| 0.13 actual daily | 10 90% of assets perform better |
Based on monthly moving average Effector Therapeutics is performing at about 10% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Effector Therapeutics by adding it to a well-diversified portfolio.
Effector Therapeutics Fundamentals Growth
Effector Stock prices reflect investors' perceptions of the future prospects and financial health of Effector Therapeutics, and Effector Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Effector Stock performance.
| Return On Equity | -9.47 | ||||
| Return On Asset | -0.83 | ||||
| Current Valuation | (5.13 M) | ||||
| Shares Outstanding | 4.7 M | ||||
| Price To Earning | 1.03 X | ||||
| Price To Book | 0 X | ||||
| Price To Sales | 69.65 X | ||||
| EBITDA | (32.78 M) | ||||
| Cash And Equivalents | 41.04 M | ||||
| Cash Per Share | 0.99 X | ||||
| Total Debt | 20.55 M | ||||
| Debt To Equity | 1.03 % | ||||
| Book Value Per Share | 0.21 X | ||||
| Cash Flow From Operations | (29.55 M) | ||||
| Earnings Per Share | (12.57) X | ||||
| Total Asset | 20.54 M | ||||
| Retained Earnings | (179.38 M) | ||||
About Effector Therapeutics Performance
Assessing Effector Therapeutics' fundamental ratios provides investors with valuable insights into Effector Therapeutics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Effector Therapeutics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. It has a collaboration agreement with Pfizer Inc. to develop inhibitors of eIF4E. eFFECTOR Therapeutics, Inc. was founded in 2012 and is headquartered in Solana Beach, California. Effector Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 12 people.Things to note about Effector Therapeutics performance evaluation
Checking the ongoing alerts about Effector Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Effector Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Effector Therapeutics is way too risky over 90 days horizon | |
| Effector Therapeutics has some characteristics of a very speculative penny stock | |
| Effector Therapeutics appears to be risky and price may revert if volatility continues | |
| Effector Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (35.81 M) with loss before overhead, payroll, taxes, and interest of (21.62 M). | |
| Effector Therapeutics currently holds about 41.04 M in cash with (29.55 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.99, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Effector Therapeutics has a frail financial position based on the latest SEC disclosures |
- Analyzing Effector Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Effector Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Effector Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Effector Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Effector Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Effector Therapeutics' stock. These opinions can provide insight into Effector Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Effector Stock Analysis
When running Effector Therapeutics' price analysis, check to measure Effector Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Effector Therapeutics is operating at the current time. Most of Effector Therapeutics' value examination focuses on studying past and present price action to predict the probability of Effector Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Effector Therapeutics' price. Additionally, you may evaluate how the addition of Effector Therapeutics to your portfolios can decrease your overall portfolio volatility.